Related Experiment Video
Updated: Mar 12, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Development of a systematic approach to pharmaceutical industry's patient assistance programs on accessing unfunded
Victoria Kletas1, Mario de Lemos1
1BC Cancer Agency, Vancouver, Canada.
Abstract:
Background New oncology drugs usually become commercially available several months before the funding decisions are made by provincial public payers. Increasingly, patient assistance programs are being set up by pharmaceutical companies in order to facilitate access of their new cancer drugs before public funding decisions are finalized. We discovered that there is a need to keep this information up to date and available in a central repository, thus we have created a centralized patient assistance chart for use by all who require information on accessing unfunded drugs in our province. Methodology The project was carried out at a publicly funded provincial cancer care organization that oversees parenteral and oral chemotherapy treatments across our province. The drug information pharmacist at this organization developed a method of scoping information on upcoming therapies by reviewing a series of recommendations made by various organizations that review oncology treatments. A standard process was developed for including information on the patient assistance chart that is available on the organizations website. Results As of May 2016, the repository contains information on 47 patient assistance programs involving 24 unfunded antineoplastic drugs for various indications. This compared to (7) when it was maintained by a single centre in 2004 and 10 when the process was first centralized in 2009. Conclusion The benefit of patient assistance program availability allows patients to access medications when provincial funding is not available. A standardized approach and methodology to evaluating information was established by our drug information pharmacist; thus allowing for a consistent approach to dissemination of information on assessing unfunded cancer drugs in our province.
Insights
Patient assistance programs help cancer patients access new, unfunded oncology drugs before public funding is approved. A centralized chart now tracks these programs, improving access to essential cancer medications.
Area of Science:
- Oncology
- Health Services Research
- Pharmacoeconomics
Background:
- New oncology drugs often precede provincial funding decisions.
- Pharmaceutical companies establish patient assistance programs (PAPs) for early access.
- A centralized, up-to-date repository for PAP information is needed.
Purpose of the Study:
- To create a centralized patient assistance chart for unfunded oncology drugs.
- To provide a central repository for accessing new cancer medications before public funding.
Main Methods:
- A provincial cancer care organization developed a systematic method for information gathering.
- Information was sourced from recommendations by oncology treatment review organizations.
- A standardized process was implemented for inclusion on a website-accessible chart.
Main Results:
- The repository contained 47 PAPs for 24 unfunded antineoplastic drugs as of May 2016.
- This represents significant growth from 7 programs in 2004 and 10 in 2009.
- The chart facilitates access to medications when provincial funding is unavailable.
Conclusions:
- Patient assistance programs are crucial for timely access to cancer medications.
- A standardized methodology ensures consistent dissemination of information on unfunded cancer drugs.
- The centralized chart improves access to essential oncology treatments.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Cancer Survival Analysis
Dosage Regimen: Individualization